Loading...
The rapid emergence of the COVID-19 pandemic with its high morbidity and substantial mortality has spurred numerous efforts aimed at prevention and effective therapy, including repurposing currently available drugs. Perhaps the most widely touted of these repurposing attempts has centered on chloroquine and hydroxychloroquine, two related antimalarial drugs with some in vitro activity against SARS-CoV-2. Now, in a randomized, double-blind, placebo-controlled trial, researchers in the U.S. and Canada have tested the use of relatively high doses of hydroxychloroquine sulfate in people with a self-reported history of recent household or occupational exposure (at less than 6 feet of spatial separation for more than 10 minutes) to someone with l…